Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy

Allergy and Asthma Proceedings

Volumn 30, Issue 2, 2009, Pages 128-138

  Andrews, Charles P ^a   Martin, Bruce G ^b   Jacobs, Robert L ^c   Mohar, Dale E ^d   Diaz, Joseph D ^b   Amar, Niran J ^e   Kaiser, Harold B ^f   Vandewalker, Mark L ^g   Bernstein, Jonathan ^h   Toler, William T ⁱ   Prillaman, Barbara A ⁱ   Dalal, Anand A ⁱ   Lee, Laurie A ⁱ   Philpot, Edward E ⁱ  

^a Diagnostics Research Group   (United States)

^b Southwest Allergy and Asthma Research   (United States)

^c Biogenics Research Institute   (United States)

^d Kerrville Allergy and Asthma   (United States)

^e Allergy and Asthma Research Institute   (United States)

^f Clinical Research Institute   (United States)

^g Clinical Research of the Ozarks   (United States)

^h Bernstein Clinical Research Center   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

Author keywords

Allergy; Antihistamine; Fexofenadine; Fluticasone furoate; Intranasal corticosteroid; Nasal symptoms; NRQLQ; Ocular symptoms; Rhinitis; Seasonal allergic rhinitis; Sleep

Indexed keywords

FEXOFENADINE; FLUTICASONE FUROATE; PLACEBO; ANDROSTANE DERIVATIVE; ANTIHISTAMINIC AGENT; DRUG DERIVATIVE; TERFENADINE;

ADULT; ARTICLE; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EPIPHORA; EYE BURNING; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NASAL PRURITUS; NIGHT SLEEP; NOSE CONGESTION; OCULAR PRURITUS; PATIENT COMPLIANCE; PEAK NASAL INSPIRATORY FLOW; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINUSITIS; SLEEP DISORDER; SNEEZING; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; COMPARATIVE STUDY; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; NOSE OBSTRUCTION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; ANDROSTADIENES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; SLEEP DISORDERS; TERFENADINE; TREATMENT OUTCOME;

EID: 67650501505     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3204     Document Type: Article

References (46)

1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
2. Ciprandi G, Klersy C, Cirillo I, et al. Quality of life in allergic rhinitis: Relationship with clinical, immunological, and functional aspects. Clin Exp Allergy 37:1528-1535, 2007.
3. Juniper EF, Guyatt GH, and Dolovich J. Assessment of health-related quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 93:413-423, 1994.
4. Bender BG. Cognitive effects of allergic rhinitis and its treatment. Immunol Allergy Clin North Am 25:301-312, 2005.
5. Pratt EL, and Craig TJ. Assessing outcomes from the sleep disturbance associated with rhinitis. Curr Opin Allergy Clin Immunol 7:249-256, 2007.
6. Léger D, Annesi-Maesano I, Carat F, et al. Allergic rhinitis and its consequences on quality of sleep. Arch Intern Med 166:1744-1748, 2006.
7. Green RJ, Davis G, and Price D. Concerns of patients with allergic rhinitis: The Allergic Rhinitis Care Programme in South Africa. Prim Care Respir J 16:299-303, 2007.
8. Szeinbach SL, Seoane-Vazquez EC, Beyer A, et al. The impact of allergic rhinitis on work productivity. Prim Care Respir J 16:98-105, 2007.
9. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 58:380-385, 2003.
10. Santos CB, Pratt EL, Hanks C, et al. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol 97:579-586, 2006.
11. Meltzer EO, Philip G, Weinstein SF, et al. Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis. Am J Rhinol 19:591-598, 2005.
12. Gurevich F, Glass C, Davies M, et al. The effect of intranasal steroid budesonide on the congestion-related sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. Allergy Asthma Proc 26:268-274, 2005.
13. Craig TJ, Hanks CD, and Fisher LH. How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis? J Allergy Clin Immunol 116:1264-1266, 2005.
14. Dykewicz MS, and Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol 81:463-468, 1998.
15. Task Force on Allergic Disorders - American Academy of Allergy, Asthma, and Immunology. The allergy report. Available online at www.theallergyreport. org; last accessed March 4, 2005.
16. 1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317:1624-1629, 1998.
17. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 769:443-448, 1997.
18. Bronsky EA, Falliers CJ, Kasier HB, et al. Effectiveness and safety of fexofenadine, a new non-sedating H1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc 19:135-141, 1998.
19. Casale T, Andrade C, and Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 20:193-198, 1999.
20. Cauwenberge PV, Juniper EF, and the Star Study Group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 30:891-899, 2000.
21. Toler T, Philpot E, Morris K, et al. An assessment of allergy patients' triggers, symptoms, and medication use. Allergy Asthma Proc 24:460, 2003 (Abs).
22. Berger WE, Godfrey JW, and Slater AL. Intranasal corticosteroids: The development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv 4:689-701, 2007.
23. McCormack PL, and Scott LJ. Fluticasone furoate: Intranasal use in allergic rhinitis. Drugs 67:1905-1915, 2007.
24. Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 29:1415-1420, 2007.
25. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 62:1078-1084, 2007.
26. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 28:216-225, 2007.
27. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430-1437, 2007.
28. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 1071-1077, 2007.
29. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 29:313-321, 2008.
30. Meltzer EO, Lee J, Tripathy I, et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatr Allergy Immunol DOI: 10.1111/j.1399-3038.2008.00773.x. , 2008.
31. Máspero JF, Rosenblut A, Finn A, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg 138:30-37, 2008.
32. Milgrom H, Kittner B, Lanier R, et al. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol 99:358-363, 2007.
33. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - A pooled analysis of three studies. Pediatr Allergy Immunol 15:253-260, 2004.
34. Wahn U, Meltzer EO, Finn AF Jr, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 111:763-769, 2003.
35. Simpson K, and Jarvis B. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301-321, 2000.
36. Markham A, and Wagstaff AJ. Fexofenadine. Drugs 55:269-274, 1998.
37. van Bavel J, Findlay SR, Hampel FC, et al. Intranasal fluticasone propionate is more effective than terfenadine tables for seasonal allergic rhinitis. Arch Intern Med 154:2699-2704, 1994.
38. Santanello NC, DeMuro-Mercon C, Shah SR, et al. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc 27:231-239, 2006.
39. Juniper EF, Rohrbaugh T, and Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhino-conjunctivitis. J Allergy Clin Immunol 111:484-490, 2003.
40. Mansfield LE, and Posey CR. Daytime sleepiness and cognitive performance improve in seasonal allergic rhinitis treated with intranasal fluticasone propionate. Allergy Asthma Proc 28:226-229, 2007.
41. Juniper EF, Williams AE, Stanford RH, et al. Determining the minimal important difference (MID) for the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire. 2007 International Society for Quality of Life Research meeting abstracts, Quality of Life Research Supplement A-86, Abs 1394. Available online at www.isoqol.org/2007mtgabstracts.pdf; last accessed Feb. 11, 2009.
42. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 34:952-957, 2004.
43. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 24:331-337, 2003.
44. Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Orolaryngol Head Neck Surg 138:129-139, 2008.
45. Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 100:194-199, 2008.
46. Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 47:118-125, 1998.